tradingkey.logo

CVRx Inc

CVRX
View Detailed Chart
6.550USD
-0.090-1.36%
Close 02/06, 16:00ETQuotes delayed by 15 min
171.57MMarket Cap
LossP/E TTM

CVRx Inc

6.550
-0.090-1.36%
Intraday
1m
30m
1h
D
W
M
D

Today

-1.36%

5 Days

-4.38%

1 Month

-17.30%

6 Months

-7.22%

Year to Date

-7.75%

1 Year

-55.47%

View Detailed Chart

TradingKey Stock Score of CVRx Inc

Currency: USD Updated: 2026-02-06

Key Insights

CVRx Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 77 out of 205 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 11.50.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

CVRx Inc's Score

Industry at a Glance

Industry Ranking
77 / 205
Overall Ranking
211 / 4521
Industry
Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

CVRx Inc Highlights

StrengthsRisks
CVRx, Inc. is a commercial-stage medical device company. The Company is focused on developing, manufacturing and commercializing advanced neuromodulation solutions for patients with cardiovascular diseases. The Company's integrated platform technology, Barostim, is designed to leverage the power of the brain and nervous system to address the imbalance of the autonomic nervous system (ANS), which causes heart failure with reduced ejection fraction (HFrEF) and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy (BAT) by sending imperceptible and persistent electrical pulses to baroreceptors located in the wall of the carotid artery to signal the brain to modulate cardiovascular function. Barostim is a minimally invasive neuromodulation device that consists of two implantable components, an implantable pulse generator (IPG) and a stimulation lead, and is programmed by a wireless clinician-controlled programmer that communicates with the IPG.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 128.28% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 51.29M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 51.29M.
Overvalued
The company’s latest PE is -3.29, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 17.05M shares, decreasing 0.31% quarter-over-quarter.
Held by PRFDX
Star Investor PRFDX holds 1.65K shares of this stock.

Analyst Rating

Based on 7 analysts
Buy
Current Rating
11.500
Target Price
+73.19%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

CVRx Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

CVRx Inc Info

CVRx, Inc. is a commercial-stage medical device company. The Company is focused on developing, manufacturing and commercializing advanced neuromodulation solutions for patients with cardiovascular diseases. The Company's integrated platform technology, Barostim, is designed to leverage the power of the brain and nervous system to address the imbalance of the autonomic nervous system (ANS), which causes heart failure with reduced ejection fraction (HFrEF) and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy (BAT) by sending imperceptible and persistent electrical pulses to baroreceptors located in the wall of the carotid artery to signal the brain to modulate cardiovascular function. Barostim is a minimally invasive neuromodulation device that consists of two implantable components, an implantable pulse generator (IPG) and a stimulation lead, and is programmed by a wireless clinician-controlled programmer that communicates with the IPG.
Ticker SymbolCVRX
CompanyCVRx Inc
CEOHykes (Kevin)
Websitehttps://www.cvrx.com/
KeyAI